These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 17055726)

  • 1. Identification of selective neuropeptide Y2 peptide agonists.
    DeCarr LB; Buckholz TM; Coish PD; Fathi Z; Fisk SE; Mays MR; O'Connor SJ; Lumb KJ
    Bioorg Med Chem Lett; 2007 Jan; 17(2):538-41. PubMed ID: 17055726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A long-acting selective neuropeptide Y2 receptor PEGylated peptide agonist reduces food intake in mice.
    DeCarr LB; Buckholz TM; Milardo LF; Mays MR; Ortiz A; Lumb KJ
    Bioorg Med Chem Lett; 2007 Apr; 17(7):1916-9. PubMed ID: 17292607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel selective neuropeptide Y2 receptor PEGylated peptide agonists reduce food intake and body weight in mice.
    Lumb KJ; DeCarr LB; Milardo LF; Mays MR; Buckholz TM; Fisk SE; Pellegrino CM; Ortiz AA; Mahle CD
    J Med Chem; 2007 May; 50(9):2264-8. PubMed ID: 17425299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel long-acting selective neuropeptide Y2 receptor polyethylene glycol-conjugated peptide agonist reduces food intake and body weight and improves glucose metabolism in rodents.
    Ortiz AA; Milardo LF; DeCarr LB; Buckholz TM; Mays MR; Claus TH; Livingston JN; Mahle CD; Lumb KJ
    J Pharmacol Exp Ther; 2007 Nov; 323(2):692-700. PubMed ID: 17671099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modifying the conserved C-terminal tyrosine of the peptide hormone PYY3-36 to improve Y2 receptor selectivity.
    Pedersen SL; Holst B; Vrang N; Jensen KJ
    J Pept Sci; 2009 Nov; 15(11):753-9. PubMed ID: 19739125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of the neuropeptide Y Y2 receptor with the specific antagonist BIIE0246 attenuates the effect of endogenous and exogenous peptide YY(3-36) on food intake.
    Abbott CR; Small CJ; Kennedy AR; Neary NM; Sajedi A; Ghatei MA; Bloom SR
    Brain Res; 2005 May; 1043(1-2):139-44. PubMed ID: 15862527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuropeptide Y (NPY) Y2 receptor-selective agonist inhibits food intake and promotes fat metabolism in mice: combined anorectic effects of Y2 and Y4 receptor-selective agonists.
    Balasubramaniam A; Joshi R; Su C; Friend LA; James JH
    Peptides; 2007 Feb; 28(2):235-40. PubMed ID: 17204349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NPY2 receptor activation in the dorsal vagal complex increases food intake and attenuates CCK-induced satiation in male rats.
    Huston NJ; Brenner LA; Taylor ZC; Ritter RC
    Am J Physiol Regul Integr Comp Physiol; 2019 Apr; 316(4):R406-R416. PubMed ID: 30726118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of independent and combined chronic anti-obese effects of NPY Y2 receptor agonist, PYY(3-36), and NPY Y5 receptor antagonist in diet-induced obese mice.
    Moriya R; Mashiko S; Ishihara A; Takahashi T; Murai T; Ito J; Mitobe Y; Oda Z; Iwaasa H; Takehiro F; Kanatani A
    Peptides; 2009 Jul; 30(7):1318-22. PubMed ID: 19394383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropeptide Y receptors in primary human brain tumors: overexpression in high-grade tumors.
    Körner M; Reubi JC
    J Neuropathol Exp Neurol; 2008 Aug; 67(8):741-9. PubMed ID: 18648328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Self-regulation of agonist activity at the Y receptors.
    Parker SL; Parker MS; Sah R; Balasubramaniam A; Sallee FR
    Peptides; 2007 Feb; 28(2):203-13. PubMed ID: 17194507
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent antiobesity effect of a short-length peptide YY-analogue continuously administered in mice.
    Nishizawa N; Niida A; Adachi Y; Masuda Y; Kumano S; Yokoyama K; Asakawa T; Hirabayashi H; Amano N; Takekawa S; Ohtaki T; Asami T
    Bioorg Med Chem Lett; 2017 Aug; 27(16):3829-3832. PubMed ID: 28684122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective role of neuropeptide Y receptor subtype Y2 in the control of gonadotropin secretion in the rat.
    Pinilla L; Fernández-Fernández R; Roa J; Castellano JM; Tena-Sempere M; Aguilar E
    Am J Physiol Endocrinol Metab; 2007 Nov; 293(5):E1385-92. PubMed ID: 17785504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological characterization and appetite suppressive properties of BMS-193885, a novel and selective neuropeptide Y(1) receptor antagonist.
    Antal-Zimanyi I; Bruce MA; Leboulluec KL; Iben LG; Mattson GK; McGovern RT; Hogan JB; Leahy CL; Flowers SC; Stanley JA; Ortiz AA; Poindexter GS
    Eur J Pharmacol; 2008 Aug; 590(1-3):224-32. PubMed ID: 18573246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorescence- and luminescence-based methods for the determination of affinity and activity of neuropeptide Y2 receptor ligands.
    Ziemek R; Brennauer A; Schneider E; Cabrele C; Beck-Sickinger AG; Bernhardt G; Buschauer A
    Eur J Pharmacol; 2006 Dec; 551(1-3):10-8. PubMed ID: 17027743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PYY3-36 as an anti-obesity drug target.
    Boggiano MM; Chandler PC; Oswald KD; Rodgers RJ; Blundell JE; Ishii Y; Beattie AH; Holch P; Allison DB; Schindler M; Arndt K; Rudolf K; Mark M; Schoelch C; Joost HG; Klaus S; Thöne-Reineke C; Benoit SC; Seeley RJ; Beck-Sickinger AG; Koglin N; Raun K; Madsen K; Wulff BS; Stidsen CE; Birringer M; Kreuzer OJ; Deng XY; Whitcomb DC; Halem H; Taylor J; Dong J; Datta R; Culler M; Ortmann S; Castañeda TR; Tschöp M
    Obes Rev; 2005 Nov; 6(4):307-22. PubMed ID: 16246216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased brain neuropeptide Y1 and Y2 receptor binding in NPY knock out mice does not result in increased receptor function.
    Gehlert DR; Shaw JL
    Peptides; 2007 Feb; 28(2):241-9. PubMed ID: 17208335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous peptide YY3-36 and Y2 receptor antagonism in the rat: effects on feeding behaviour.
    Scott V; Kimura N; Stark JA; Luckman SM
    J Neuroendocrinol; 2005 Jul; 17(7):452-7. PubMed ID: 15946163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indolyl and dihydroindolyl N-glycinamides as potent and in vivo active NPY5 antagonists.
    Wu L; Lu K; Packiarajan M; Jubian V; Chandrasena G; Wolinsky TC; Walker MW
    Bioorg Med Chem Lett; 2012 Mar; 22(6):2167-71. PubMed ID: 22361135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-expression of neuropeptide Y Y1 and Y5 receptors results in heterodimerization and altered functional properties.
    Gehlert DR; Schober DA; Morin M; Berglund MM
    Biochem Pharmacol; 2007 Dec; 74(11):1652-64. PubMed ID: 17897631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.